160 related articles for article (PubMed ID: 8786651)
1. Prospects for Chemoprevention of Cancers of the Cervix, Endometrium and Ovary: Surrogate Endpoints and Design of Clinical Trials. Conference proceedings. Oxnard, California, February 1-5, 1995.
J Cell Biochem Suppl; 1995; 23():1-250. PubMed ID: 8786651
[No Abstract] [Full Text] [Related]
2. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention trials and surrogate end point biomarkers in the cervix.
Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
[TBL] [Abstract][Full Text] [Related]
4. Prevention of cancers of the breast, endometrium and ovary.
Pike MC; Pearce CL; Wu AH
Oncogene; 2004 Aug; 23(38):6379-91. PubMed ID: 15322512
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of Breast Cancer: Surrogate Endpoints and Agents in Short-Term Clinical Trials. Proceedings of a workshop. Lake Tahoe, California, October 6-10, 1993.
J Cell Biochem Suppl; 1993; 17G():1-263. PubMed ID: 7911859
[No Abstract] [Full Text] [Related]
6. Surrogate endpoint biomarkers for cervical cancer chemopreventive trials.
Ruffin MT; Ogaily MS; Johnston CM; Gregoire L; Lancaster WD; Brenner DE
J Cell Biochem Suppl; 1995; 23():113-24. PubMed ID: 8747385
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of cancer.
Tsao AS; Kim ES; Hong WK
CA Cancer J Clin; 2004; 54(3):150-80. PubMed ID: 15195789
[TBL] [Abstract][Full Text] [Related]
8. Hormonal chemoprevention of cancer in women.
Henderson BE; Ross RK; Pike MC
Science; 1993 Jan; 259(5095):633-8. PubMed ID: 8381558
[TBL] [Abstract][Full Text] [Related]
9. Hormonal contraception and chemoprevention of female cancers.
Pike MC; Spicer DV
Endocr Relat Cancer; 2000 Jun; 7(2):73-83. PubMed ID: 10903525
[TBL] [Abstract][Full Text] [Related]
10. Commentary: Does tubal sterilization reduce the risk of gynaecological cancers?
Purdie DM
Int J Epidemiol; 2004 Jun; 33(3):603-4. PubMed ID: 15163643
[No Abstract] [Full Text] [Related]
11. Potential criteria for cohort selection in chemoprevention trials of uterine adenocarcinoma.
Baker VV
J Cell Biochem Suppl; 1995; 23():184-8. PubMed ID: 8747395
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of mammary, cervix and nervous system carcinogenesis in animals using cultured Panax ginseng drugs and preliminary clinical trials in patients with precancerous lesions of the esophagus and endometrium.
Bespalov VG; Alexandrov VA; Limarenko AY; Voytenkov BO; Okulov VB; Kabulov MK; Peresunko AP; Slepyan LI; Davydov VV
J Korean Med Sci; 2001 Dec; 16 Suppl(Suppl):S42-53. PubMed ID: 11748376
[TBL] [Abstract][Full Text] [Related]
14. From carcinogenesis to clinical interventions for cancer prevention.
Greenwald P
Toxicology; 2001 Sep; 166(1-2):37-45. PubMed ID: 11518609
[TBL] [Abstract][Full Text] [Related]
15. The role of aspirin in the prevention of ovarian, endometrial and cervical cancers.
Joharatnam-Hogan N; Cafferty FH; Macnair A; Ring A; Langley RE
Womens Health (Lond); 2020; 16():1745506520961710. PubMed ID: 33019903
[TBL] [Abstract][Full Text] [Related]
16. Cancer chemoprevention.
Brenner DE
Crit Rev Oncol Hematol; 2000 Mar; 33(3):155-6. PubMed ID: 10789489
[No Abstract] [Full Text] [Related]
17. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers and their use in cervical cancer chemoprevention.
Vlastos AT; Schottenfeld D; Follen M
Crit Rev Oncol Hematol; 2003 Jun; 46(3):261-73. PubMed ID: 12791426
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor markers in gynecological tumors.
Rustin GJ
Curr Opin Oncol; 1996 Sep; 8(5):426-31. PubMed ID: 8914810
[TBL] [Abstract][Full Text] [Related]
20. Cancer chemoprevention.
Greenwald P
BMJ; 2002 Mar; 324(7339):714-8. PubMed ID: 11909790
[No Abstract] [Full Text] [Related]
[Next] [New Search]
